Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer

被引：1
|
作者：
Hasenburg, A. [1 ]
van de Velde, C. J. H. [2 ]
Seynaeve, C. [3 ]
Rea, D. W. [4 ]
Vannetzel, J. [5 ]
Paridaens, R. [6 ]
Markopoulos, C. [7 ]
Hozumi, Y. [8 ]
Putter, H. [2 ]
Jones, S. E. [9 ]
机构：
[1] Univ Med Ctr, Freiburg, Germany
[2] Univ Med Ctr, Leiden, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Inst Sein Henri Hartmann, Neuilly Sur Seine, France
[6] Univ Hosp Gasthuisberg, Louvain, Belgium
[7] Univ Med Sch, Athens, Greece
[8] Jichi Med Univ, Shimotsuke, Japan
[9] US Oncol Res, Med Oncol, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70047-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [31] TAMOXIFEN (T) AND EXEMESTANE (E) IN EARLY BREAST CANCER PATIENTS: ENDOMETRIAL EFFECTS. A RANDOMIZED PHASE III TRIAL
    Garrone, Ornella
    Favilla, Bruno
    Occelli, Marcella
    Principe, Ernesto
    Giubergia, Silvia
    Merlano, Marco
    ANNALS OF ONCOLOGY, 2004, 15 : 16 - 16
  • [32] Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
    Norikazu Masuda
    Kenji Tamura
    Hiroyuki Yasojima
    Akihiko Shimomura
    Masataka Sawaki
    Min-Jung Lee
    Akira Yuno
    Jane Trepel
    Ryoko Kimura
    Yozo Nishimura
    Shigehira Saji
    Hiroji Iwata
    BMC Cancer, 21
  • [33] Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
    Masuda, Norikazu
    Tamura, Kenji
    Yasojima, Hiroyuki
    Shimomura, Akihiko
    Sawaki, Masataka
    Lee, Min-Jung
    Yuno, Akira
    Trepel, Jane
    Kimura, Ryoko
    Nishimura, Yozo
    Saji, Shigehira
    Iwata, Hiroji
    BMC CANCER, 2021, 21 (01)
  • [34] ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer
    Ellis, M. J.
    Babiera, G.
    Unzeitig, G. W.
    Marcom, P. K.
    Guenther, J. M.
    Deshryver, F. K.
    Allred, D. C.
    Suman, V.
    Hunt, K.
    Olson, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [35] Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
    van Nes, J. G. H.
    Seynaeve, C.
    Maartense, E.
    Roumen, R. M. H.
    de Jong, R. S.
    Beex, L. V. A. M.
    Kranenbarg, W. M. Meershoek-Klein
    Putter, H.
    Nortier, J. W. R.
    van de Velde, C. J. H.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 974 - 982
  • [36] Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
    Krop, Ian
    Abramson, Vandana
    Colleoni, Marco
    Traina, Tiffany
    Holmes, Frankie
    Estevez, Laura
    Hart, Lowell
    Awada, Ahmad
    Zamagni, Claudio
    Morris, Patrick
    Schwartzberg, Lee
    Chan, Stephen
    Wheatley, Duncan
    Gucalp, Ayca
    Biganzoli, Laura
    Steinberg, Joyce
    Gianni, Luca
    Trudeau, Maureen
    Tudor, Iulia Cristina
    Markova, Denka
    Barry, Elly
    Tarazi, Jamal
    Stewart, Ross
    Winer, Eric
    Yardley, Denise A.
    CANCER RESEARCH, 2018, 78 (04)
  • [37] Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
    Machin, D
    Andersen, KW
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (09): : 659 - 659
  • [38] Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
    Rutqvist, LE
    Hatschek, T
    Ryden, S
    Bergh, J
    Bengtsson, NO
    Carstenssen, J
    Nordenskjold, B
    Wallgren, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) : 1543 - 1549
  • [39] Endometrial effects of tamoxifen (T) and exemestane (E) in early breast cancer patients (EBCP). A randomized phase III trial.
    Garrone, O
    Principe, E
    Occelli, M
    Favilla, B
    Giubergia, S
    Rattazzi, PD
    Merlano, M
    Gen, SC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 81S - 81S
  • [40] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
    Chia, Stephen
    Gradishar, William
    Mauriac, Louis
    Bines, Jose
    Amant, Frederic
    Federico, Miriam
    Fein, Luis
    Romieu, Gilles
    Buzdar, Aman
    Robertson, John F. R.
    Brufsky, Adam
    Possinger, Kurt
    Rennie, Pamela
    Sapunar, Francisco
    Lowe, Elizabeth
    Piccart, Martine
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1664 - 1670
12345